Epidemiology, health policy and outcomes
Michelle Petri, MD, MPH
Johns Hopkins University School of Medicine
Timonium, MD, United States
Disclosure(s): Amgen: Advisor or Review Panel Member (Terminated, April 30, 2023); AnaptysBio: Advisor or Review Panel Member (Terminated, January 31, 2023); Annexon Bio: Advisor or Review Panel Member (Ongoing); Argenx: Advisor or Review Panel Member (Ongoing); Arhros-Focus Med/Ed: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); AstraZeneca: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Aurinia: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boxer Capital: Consultant (Ongoing); Cabaletto Bio: Consultant (Ongoing); Caribou Biosciences: Consultant (Ongoing); CTI Clinical Trial and Consulting Services: Advisor or Review Panel Member (Ongoing); CVS Health: Advisor or Review Panel Member (Ongoing); Eli Lilly: Grant/Research Support (Terminated, December 30, 2023); Emergent Biosolutions: Advisor or Review Panel Member (Ongoing); Escient Pharmaceuticals: Advisor or Review Panel Member (Ongoing); Exagen: Grant/Research Support (Ongoing); Exo Therapeutics: Consultant (Ongoing); Gentibio: Consultant (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Horizon Therapeutics: Consultant (Ongoing); iCell Gene Therapeutics: Consultant (Ongoing); Idorsia Pharmaceuticals: Consultant (Terminated, July 31, 2022); IQVIA: Advisor or Review Panel Member (Ongoing); Janssen: Grant/Research Support (Ongoing); Kira Pharmaceuticals: Consultant (Terminated, March 31, 2023); MedShr: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, March 31, 2022); Merck/EMD Serono: Advisor or Review Panel Member (Ongoing); Nexstone Immunology: Consultant (Ongoing); Nimbus Lakshmi: Consultant (Ongoing); Proviant: Consultant (Ongoing); Regeneron Pharmaceuticals: Consultant (Ongoing); Sanofi: Consultant (Terminated, September 30, 2022); Seismic Therapeutic: Consultant (Ongoing); Sinomab Biosciences: Consultant (Ongoing); Takeda: Advisor or Review Panel Member (Ongoing); Tenet Medicines Inc: Consultant (Ongoing); TG Therapeutics: Advisor or Review Panel Member (Ongoing); UCB: Consultant (Terminated, January 31, 2022); Zydus: Consultant (Ongoing)
John Stone, MD,MPH
Professor of Medicine; The Edward Fox Chair in Medicine
Massachusetts General Hospital , Harvard Medical School
Concord, MA, United States
Disclosure(s): Abvie: Consultant (Ongoing); Amgen: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Argenx: Consultant (Ongoing); Aztrazeneca: Consultant (Terminated, December 31, 2022); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Celgene: Consultant (Terminated, December 31, 2022); Chemocentryx: Consultant (Terminated, December 31, 2022); Chugai: Consultant (Terminated, December 31, 2022); GSK: Consultant (Terminated, December 31, 2022); Horizon Therapeutics: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); InflaRx: Consultant (Terminated, December 31, 2022); IQVIA: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing); Kyverna: Consultant (Terminated, December 31, 2022); Mirabio: Consultant (Terminated, December 31, 2022); NIH: Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing); PPD: Consultant (Ongoing); Prometheus: Consultant (Ongoing); Q32: Consultant (Ongoing); Regeneron: Consultant (Terminated, December 31, 2022); Roche-Genentech: Consultant (Ongoing); Roivant: Consultant (Terminated, December 31, 2022); Sanofi: Consultant (Ongoing), Grant/Research Support (Ongoing); Spruce Biosciences: Consultant (Terminated, December 31, 2022); Star Therapeutics: Consultant (Ongoing); Steritas: Chair, Scientific Advisory Board (no fiduciary responsibilities) (Ongoing); ZenasBio: Consultant (Ongoing)
Beth Wallace, MD,MS
Michigan Medicine, VA Ann Arbor Healthcare System
Ann Arbor, Michigan, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
In this session, leading researchers will review timely and unresolved issues centered on glucocorticoid use within rheumatology. Discussion topics will cover: 1) what constitutes a ”safe” glucocorticoid dose and challenges in interpreting data from clinical studies on glucocorticoid-induced adverse effects; 2) areas of uncertainty regarding glucocorticoid tapering, and an overview of personalized taper strategies that could incorporate patient phenotypes; and 3) difficulties in accurately capturing glucocorticoid exposure and inferring adherence from prescription data and how best to approach limitations inherent to varied databases.
Speaker: John Stone, MD,MPH – Massachusetts General Hospital , Harvard Medical School
Speaker: Michelle Petri, MD, MPH – Johns Hopkins University School of Medicine
Speaker: Beth Wallace, MD,MS – Michigan Medicine, VA Ann Arbor Healthcare System